Genetic testing and risk assessment for spinal muscular atrophy (SMA)
- PMID: 12436240
- DOI: 10.1007/s00439-002-0828-x
Genetic testing and risk assessment for spinal muscular atrophy (SMA)
Abstract
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive diseases, affecting approximately 1 in 10,000 live births, and with a carrier frequency of approximately 1 in 50. Because of gene deletion or conversion, SMN1 exon 7 is homozygously absent in approximately 94% of patients with clinically typical SMA. Approximately 30 small intragenic SMN1 mutations have also been described. These mutations are present in many of the approximately 6% of SMA patients who do not lack both copies of SMN1, whereas SMA of other patients without a homozygous absence of SMN1 is unrelated to SMN1. A commonly used polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) assay can be used to detect a homozygous absence of SMN1 exon 7. SMN gene dosage analyses, which can determine the copy numbers of SMN1 and SMN2 (an SMN1 homolog and a modifier for SMA), have been developed for SMA carrier testing and to confirm that SMN1 is heterozygously absent in symptomatic individuals who do not lack both copies of SMN1. In conjunction with SMN gene dosage analysis, linkage analysis remains an important component of SMA genetic testing in certain circumstances. Genetic risk assessment is an essential and integral component of SMA genetic testing and impacts genetic counseling both before and after genetic testing is performed. Comprehensive SMA genetic testing, comprising PCR-RFLP assay, SMN gene dosage analysis, and linkage analysis, combined with appropriate genetic risk assessment and genetic counseling, offers the most complete evaluation of SMA patients and their families at this time. New technologies, such as haploid analysis techniques, may be widely available in the future.
Similar articles
-
Spinal muscular atrophy: molecular genetics and diagnostics.Expert Rev Mol Diagn. 2004 Jan;4(1):15-29. doi: 10.1586/14737159.4.1.15. Expert Rev Mol Diagn. 2004. PMID: 14711346 Review.
-
An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).Hum Mutat. 2000;15(3):228-37. doi: 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9. Hum Mutat. 2000. PMID: 10679938 Review.
-
Genetic study of SMA patients without homozygous SMN1 deletions: identification of compound heterozygotes and characterisation of novel intragenic SMN1 mutations.Hum Genet. 2002 Mar;110(3):257-63. doi: 10.1007/s00439-002-0681-y. Epub 2002 Feb 8. Hum Genet. 2002. PMID: 11935338
-
Molecular analysis and prenatal prediction of spinal muscular atrophy in Chinese patients by the combination of restriction fragment length polymorphism analysis, denaturing high-performance liquid chromatography, and linkage analysis.Arch Neurol. 2007 Feb;64(2):225-31. doi: 10.1001/archneur.64.2.225. Arch Neurol. 2007. PMID: 17296838
-
Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.Hum Mutat. 2005 Jan;25(1):64-71. doi: 10.1002/humu.20111. Hum Mutat. 2005. PMID: 15580564
Cited by
-
Spinal muscular atrophy--recent therapeutic advances for an old challenge.Nat Rev Neurol. 2015 Jun;11(6):351-9. doi: 10.1038/nrneurol.2015.77. Epub 2015 May 19. Nat Rev Neurol. 2015. PMID: 25986506 Review.
-
An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival.Genome Res. 2006 Sep;16(9):1084-90. doi: 10.1101/gr.5268806. Epub 2006 Aug 9. Genome Res. 2006. PMID: 16899656 Free PMC article.
-
Molecular characterization of SMN copy number derived from carrier screening and from core families with SMA in a Chinese population.Eur J Hum Genet. 2010 Sep;18(9):978-84. doi: 10.1038/ejhg.2010.54. Epub 2010 May 5. Eur J Hum Genet. 2010. PMID: 20442745 Free PMC article.
-
Nonsense-mediated messenger RNA decay of survival motor neuron 1 causes spinal muscular atrophy.Hum Genet. 2008 Mar;123(2):141-53. doi: 10.1007/s00439-007-0455-7. Epub 2008 Jan 3. Hum Genet. 2008. PMID: 18172693
-
Bayesian risk assessment for autosomal recessive diseases: fetal echogenic bowel with one or no detectable CFTR mutation.J Med Genet. 2004 May;41(5):e70. doi: 10.1136/jmg.2003.015065. J Med Genet. 2004. PMID: 15121798 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Associated data
- GDB/120378
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
